A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
AYTU BIOPHARMA, INC
AYTU
$14M
Mkt Cap
$2.16
+0.00%
AYTU BIOPHARMA, INC (AYTU) has a 5-year average return on invested capital (ROIC) of -47.2%. This is below average and may indicate limited pricing power.
AYTU BIOPHARMA, INC (AYTU) has a market capitalization of $23M. It is classified as a small-cap stock.
AYTU BIOPHARMA, INC (AYTU) does not currently pay a regular dividend.
AYTU BIOPHARMA, INC (AYTU) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AYTU BIOPHARMA, INC (AYTU) reported annual revenue of $66 million in its most recent fiscal year, based on SEC EDGAR filings.
AYTU BIOPHARMA, INC (AYTU) has a net profit margin of -20.4%. The company is currently unprofitable.
AYTU BIOPHARMA, INC (AYTU) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ITEM 1. BUSINESS Company Overview Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580. Our strategy is to become a leading pharmaceutical company that improves the lives of patients.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 63M | 66M | 65M | 107M | 97M | 66M |
| Net Income | -24M | -14M | -16M | -17M | -109M | -58M |
| EPS | $-2.35 | $-2.16 | $-2.86 | $-5.11 | $-1,480.20 | $-69.60 |
| Free Cash Flow | -698K | -2.2M | -1.7M | -5.1M | -29M | -28M |
| ROIC | -5.6% | -39.6% | -5.7% | -30.1% | -110.4% | -50.1% |
| Gross Margin | 66.8% | 69.0% | 75.3% | 62.0% | 54.1% | 44.5% |
| Debt/Equity | 0.83 | 0.67 | 0.55 | 0.42 | 0.43 | 0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.7M | -7.8M | -1.6M | -17M | -110M | -59M |
| Operating Margin | -13.9% | -11.8% | -2.4% | -15.9% | -113.7% | -89.7% |
| ROE | -172.1% | -58.1% | -47.2% | -40.8% | -119.6% | -50.1% |
| Shares Outstanding | 11M | 6M | 6M | 3M | 0M | 1M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | 262K | 2.6M | 3.2M | 3.7M | N/A | 28M | 66M | 97M | 107M | 65M | 66M | 63M |
| Gross Margin | N/A | 66.3% | 62.6% | 56.0% | 44.0% | N/A | 70.0% | 44.5% | 54.1% | 62.0% | 75.3% | 69.0% | 66.8% |
| R&D | 3.9M | 3.2M | 6.1M | 960K | 168K | 589K | 1.7M | 5.6M | 13M | 4.1M | 2.8M | 1.3M | 378K |
| SG&A | 2.3M | 4.0M | 8.5M | 17M | 18M | 19M | 35M | 26M | 31M | 29M | 20M | 17M | 18M |
| EBIT | -6.3M | -7.6M | -22M | -20M | -20M | -17M | -21M | -59M | -110M | -17M | -1.6M | -7.8M | -8.7M |
| Op. Margin | N/A | -2915.5% | -847.0% | -624.7% | -538.2% | N/A | -76.5% | -89.7% | -113.7% | -15.9% | -2.4% | -11.8% | -13.9% |
| Net Income | -5.6M | N/A | N/A | N/A | N/A | -27M | -14M | -58M | -109M | -17M | -16M | -14M | -24M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -49.3% | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% | -39.0% |
| Non-Recurring | 0 | 0 | 0 | 504K | 238K | 0 | 867K | 18M | 66M | 5.8M | 2.2M | 11M | 0 |
| Returns on Capital | |||||||||||||
| ROIC | -93.4% | N/A | N/A | N/A | N/A | -38.3% | -26.7% | -50.1% | -110.4% | -30.1% | -5.7% | -39.6% | -5.6% |
| ROE | -73.5% | N/A | N/A | N/A | N/A | -264.5% | -26.7% | -50.1% | -119.6% | -40.8% | -47.2% | -58.1% | -172.1% |
| ROA | -92.8% | N/A | N/A | N/A | N/A | -97.3% | -14.5% | -27.8% | -53.9% | -12.4% | -12.4% | -11.2% | -20.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -5.5M | -6.6M | -11M | -14M | -16M | -14M | -28M | -26M | -29M | -5.1M | -1.4M | -1.9M | -595K |
| Free Cash Flow | -5.5M | -6.6M | -11M | -14M | -16M | -14M | -28M | -28M | -29M | -5.1M | -1.7M | -2.2M | -698K |
| Owner Earnings | -6.1M | -7.8M | -12M | -21M | -19M | -18M | -35M | -39M | -44M | -20M | -12M | -6.4M | 40K |
| CapEx | 9K | 0 | 253K | 112K | 75K | 60K | 0 | 2.3M | 0 | 0 | 329K | 228K | 103K |
| Maint. CapEx | 97K | 118K | 875K | 4.4M | 2.6M | 2.7M | 5.7M | 9.2M | 10M | 8.8M | 8.3M | 3.9M | -1.3M |
| Growth CapEx | 0 | N/A | 0 | 0 | 0 | 0 | N/A | 0 | N/A | N/A | 0 | 0 | 1.4M |
| D&A | 97K | 118K | 875K | 4.4M | 2.6M | 2.7M | 5.7M | 9.2M | 10M | 8.8M | 8.3M | 3.9M | -1.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 500K | 1.0M | 903K | 2.5M | 597K | 1.0M | 1.1M | 3.6M | 5.2M | 6.0M | 2.4M | 576K | 649K |
| Debt Repayment | 0 | 0 | 298K | 0 | 0 | 0 | 19M | 968K | 16M | 96K | 16M | 1.9M | 1.9M |
| Balance Sheet | |||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | -11M | -47M | -33M | -451K | -6.6M | -4.9M | -18M | -18M |
| Cash & Equiv. | 2.6M | 7.4M | 8.1M | 802K | 7.0M | 11M | 48M | 50M | 19M | 23M | 20M | 31M | 30M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 180K | 15M | 15M | 11M | 11M | 10.0M |
| Debt/Equity | 1.24 | 0.16 | 1.41 | 2.75 | 0.57 | 0.00 | 0.01 | 0.12 | 0.43 | 0.42 | 0.55 | 0.67 | 0.83 |
| Interest Coverage | -139.3 | -66.4 | -4.0 | -7.9 | -26.3 | -31.5 | -8.1 | -9811.7 | -122.1 | -3.4 | -0.3 | -2.1 | -2.1 |
| Equity | 5.4M | 16M | 10M | 4.0M | 13M | 7.1M | 95M | 138M | 44M | 39M | 28M | 19M | 14M |
| Total Assets | 12M | 18M | 24M | 15M | 21M | 35M | 153M | 266M | 138M | 136M | 118M | 124M | 122M |
| Total Liabilities | 6.6M | 2.6M | 14M | 11M | 7.6M | 28M | 58M | 128M | 93M | 97M | 90M | 105M | 1.8M |
| Intangibles | 700K | 629K | 297K | 271K | 246K | 19M | 49M | 85M | 71M | 59M | 52M | 42M | 44M |
| Retained Earnings | -11M | -18M | -47M | -69M | -79M | -106M | -120M | -178M | -287M | -304M | -320M | -334M | -342M |
| Working Capital | -2.8M | 6.6M | 16K | -582K | 6.1M | 10M | 47M | -4.2M | -4.5M | 3.8M | -337K | 16M | 11M |
| Current Assets | 3.3M | 8.0M | 10M | 3.0M | 9.5M | 15M | 75M | 105M | 60M | 73M | 62M | 79M | 76M |
| Current Liabilities | 6.1M | 1.5M | 10M | 3.6M | 3.4M | 5.4M | 29M | 109M | 64M | 69M | 62M | 63M | 66M |
| Per Share Data | |||||||||||||
| EPS | -25.60 | -8,700.48 | -69,919.20 | -2,318.40 | -1,714.72 | -97.44 | -421.40 | -69.60 | -1,480.20 | -5.11 | -2.86 | -2.16 | -2.35 |
| Owner EPS | -27.99 | N/A | N/A | N/A | N/A | -63.14 | -1,087.98 | -46.26 | -601.68 | -5.99 | -2.17 | -1.02 | 0.00 |
| Book Value | 24.64 | N/A | N/A | N/A | N/A | 25.45 | 2,939.53 | 164.26 | 602.92 | 11.79 | 5.00 | 3.02 | 1.32 |
| Cash Flow/Share | -25.25 | N/A | N/A | N/A | N/A | -49.67 | -877.82 | -31.00 | -392.21 | -1.54 | -0.25 | -0.31 | -2.40 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.2M | N/A | N/A | N/A | N/A | 0.3M | 0.0M | 0.8M | 0.1M | 3.3M | 5.5M | 6.3M | 10.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 3.2 | 1.5 | 37.3 | 99.1 | 7.1 | 33.6 | 4.8 | 2.4 | 1.3 | 0.2 | 1.0 | 1.1 | 1.6 |
| Price/Sales | N/A | 645.9 | 730.6 | 405.9 | 296.2 | N/A | 12.3 | 8.6 | 2.3 | 0.2 | 0.4 | 0.3 | 0.4 |
| FCF Yield | -32.4% | -28.7% | -2.9% | -3.5% | -16.8% | -5.8% | -6.2% | -8.7% | -48.3% | -56.0% | -5.9% | -10.4% | -3.0% |
| Market Cap | 17M | 23M | 376M | 396M | 96M | 238M | 457M | 324M | 60M | 9.2M | 29M | 21M | 23M |
| Avg. Price | 3,580,487.83 | 2,667,662.87 | 1,861,944.66 | 145,179.45 | 12,257.39 | 450.80 | 247.09 | 180.84 | 40.27 | 4.20 | 2.59 | 1.87 | 2.16 |
| Year-End Price | 2,341,463.50 | 364,800.00 | 374,400.00 | 44,000.00 | 1,080.00 | 378.00 | 332.00 | 103.80 | 10.80 | 1.49 | 2.92 | 2.10 | 2.16 |
AYTU BIOPHARMA, INC passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 61.0%.
AYTU BIOPHARMA, INC (AYTU) has a debt-to-equity ratio of 0.67. This indicates moderate leverage.
AYTU BIOPHARMA, INC (AYTU) reported earnings per share (EPS) of $-2.16 in its most recent fiscal year.
AYTU BIOPHARMA, INC (AYTU) has a return on equity (ROE) of -58.1%. A negative ROE may indicate losses or negative equity.
AYTU BIOPHARMA, INC (AYTU) has a 5-year average gross margin of 61.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for AYTU BIOPHARMA, INC (AYTU), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AYTU BIOPHARMA, INC (AYTU) has a book value per share of $3.02, based on its most recent annual SEC filing.
No recent press releases.